CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus

Date publication

janvier 2016

Journal

European journal of radiology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr AYAV Ahmet , Pr BRONOWICKI Jean-Pierre

Tous les auteurs :
Gavanier M, Ayav A, Sellal C, Orry X, Claudon M, Bronowicki JP, Laurent V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26724654

Résumé

The first aim was to compare Response Evaluation Criteria in Solid Tumor (RECIST) 1.1, modified Response Evaluation Criteria in Solid Tumor (mRECIST), Choi and European Association for the Study of the Liver (EASL) evaluations to assess the response to sorafenib for hepatocellular carcinoma (HCC). The second aim was to describe the evolution of HCC and to identify whether some imaging features are predictive of the absence of response.

Mots clés

Adult, Aged, Antineoplastic Agents, therapeutic use, Carcinoma, Hepatocellular, diagnostic imaging, Female, Humans, Liver, diagnostic imaging, Liver Neoplasms, diagnostic imaging, Male, Middle Aged, Niacinamide, analogs & derivatives, Phenylurea Compounds, therapeutic use, Proportional Hazards Models, Response Evaluation Criteria in Solid Tumors, Retrospective Studies, Survival Analysis, Tomography, X-Ray Computed, Treatment Outcome

Référence

Eur J Radiol. 2016 Jan;85(1):103-12